AstraZeneca and Amgen announced that a Phase 3 trial of Tezspire (tezepelumab) showed a statistically significant and ...

Fidelity Diversified International Fund is a broadly diversified international equity strategy that seeks capital growth by ...

Halozyme Therapeutics (NASDAQ:HALO) announced on Thursday its plans to acquire German drug developer Evotec SE ADR (NASDAQ:EVO) in a deal valued at approximately 2 billion euros ($2.10 billion), to ...

Omega Therapeutics is halting work on its only clinical-stage candidate as part of a strategic refocus centered on three ...

In case you’ve missed it, ASX COVID-era tech darling Bigtincan Holdings (ASX:BTH) has received a takeover offer from the ...

Halozyme intends to purchase all the shares of Evotec at 11 euros per share, which represents a premium of 27.5% to Evotec's last close price. U.S.-listed shares of Evotec were up 6.3%, while those of ...

German drugmaker Evotec is attracting takeover interest from U.S.-based Halozyme Therapeutics , Bloomberg News reported on Thursday.

Plus: How AI can make it easier to find drugs from nature and a study suggests Ozempic could treat alcoholism.

EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

A smart beta exchange traded fund, the FlexShares International Quality Dividend ETF (IQDF) debuted on 04/12/2013, and offers broad exposure to the World ETFs category of the market.